Vanguard Personalized Indexing Management LLC Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vanguard Personalized Indexing Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 17.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 7,153 shares of the biopharmaceutical company’s stock after acquiring an additional 1,067 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,738,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Amalgamated Bank grew its stake in Alnylam Pharmaceuticals by 3.7% during the 2nd quarter. Amalgamated Bank now owns 8,354 shares of the biopharmaceutical company’s stock worth $2,030,000 after buying an additional 301 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its stake in Alnylam Pharmaceuticals by 15.3% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,030 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 270 shares during the last quarter. E Fund Management Co. Ltd. grew its stake in Alnylam Pharmaceuticals by 75.1% during the 2nd quarter. E Fund Management Co. Ltd. now owns 4,926 shares of the biopharmaceutical company’s stock worth $1,197,000 after buying an additional 2,112 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Alnylam Pharmaceuticals by 4.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 266,206 shares of the biopharmaceutical company’s stock worth $64,702,000 after buying an additional 11,027 shares during the last quarter. Finally, Dai ichi Life Insurance Company Ltd purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $262,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Evercore ISI increased their price objective on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. Needham & Company LLC increased their price objective on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Leerink Partners increased their price objective on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday, June 25th. Finally, Bank of America increased their price objective on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $279.14.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $273.88 on Friday. The stock has a fifty day moving average price of $260.11 and a 200 day moving average price of $199.07. The stock has a market cap of $34.64 billion, a PE ratio of -102.19 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The business’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.21) earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jeffrey V. Poulton sold 1,605 shares of the firm’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $231.00, for a total value of $370,755.00. Following the transaction, the chief financial officer now directly owns 28,892 shares of the company’s stock, valued at approximately $6,674,052. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 103,148 shares of company stock valued at $25,658,824. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.